Skip to main content
Midas Edge

IGC Pharma, Inc.

For the period ended Mar 31, 2026. Filed May 15, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 15, 2026

IGC$0.20-4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’EQUITY

Number of Common SharesCommon Stock and Additional Paid in Capital ($)Accumulated Deficit ($)Accumulated Other Comprehensive Loss ($)Total Stockholders’ Equity ($)
Balances as of December 31, 202478,203129,307(119,589)(3,459)6,259
Common stock-based compensation & expenses, net-458--458
Common stock subscribed but not yet issued-----
Issuance of common stock through offering (net of expenses)2,675805--805
Cancellation/forfeiture of shares-----
Common stock subscribed-----
Other adjustments--43(43)-
Net loss--(1,198)-(1,198)
Foreign currency translation---66
Balances as of March 31, 202580,878130,570(120,744)(3,496)6,330
Balances as of December 31, 202595,038138,014(124,890)(5,701)7,423
Common stock-based compensation & expenses, net2,3571,021--1,021
Common stock subscribed but not yet issued-(264)--(264)
Issuance of common stock through offering (net of expenses)1,401351--351
Cancellation/forfeiture of shares-----
Common stock subscribed-----
Other adjustments-----
Net loss--(2,402)-(2,402)
Foreign currency translation---(8)(8)
Balances as of March 31, 202698,796139,122(127,292)(5,709)6,121

| March 31, 2026, Form 10-Q

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.